News Column

Reports Outline Prostate Cancer Findings from Ruder Boskovic Institute

February 19, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Oncology have been published. According to news reporting originating from Zagreb, Croatia, by NewsRx correspondents, research stated, "Prostate cancer remains one of the most common malignancies in men. Besides surgical resection, treatments for prostate cancer include hormone therapy, chemotherapy, and radiation therapy."

Our news editors obtained a quote from the research from Ruder Boskovic Institute, "Advancement of prostate cancer to an androgen-independent state limits the potential of conventional therapeutic approaches. Bortezomib, an FDA-approved proteosomal inhibitor for the treatment of myeloid leukemia, has been shown to have a positive effect on the inhibition of prostate cancer growth. Unfortunately, bortezomib has a very narrow therapeutic window, which can lead to severe side effects. Elastin-like polypeptide (ELP) is a genetically engineered, thermally responsive macromolecular carrier that enables a targeted delivery of the bound molecule because of its soluble property under normal physiologic conditions. In addition, ELP aggregates in response to mild hyperthermia. Using ELP as a carrier, it is possible to improve the pharmacological properties of the therapeutic drug as well as reduce toxicity in normal tissues. In this work, we have investigated the combination treatment of androgen-independent prostate cancer cells with bortezomib and the C-terminal part of the p21(WAF1/CIP1) protein bound to the ELP carrier. We have found that combination treatment with bortezomib and ELP-bound p21(WAF1/CIP1) protein leads to increased cell cycle arrest as well as apoptosis with respect to single treatments."

According to the news editors, the research concluded: "We believe that this approach represents a promising direction for the treatment of androgen-independent prostate cancer."

For more information on this research see: Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines. Anti-Cancer Drugs, 2014;25(2):189-199. Anti-Cancer Drugs can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Lippincott Williams and Wilkins - www.lww.com; Anti-Cancer Drugs - journals.lww.com/anti-cancerdrugs/pages/default.aspx)

The news editors report that additional information may be obtained by contacting A.M. Mikecin, Rudjer Boskovic Inst, Dept. of Mol Med, Zagreb, Croatia. Additional authors for this research include L.R. Walker, M. Kuna and D. Raucher (see also Oncology).

Keywords for this news article include: Antineoplastics, Pharmaceuticals, Drugs, Zagreb, Europe, Croatia, Genetics, Hormones, Oncology, Treatment, Bortezomib, Chemotherapy, Prostate Cancer, Radiation Therapy, Prostatic Neoplasms, Androgens and Anabolic Steroids

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools